Khalid A Alburikan1, Ahmed Aldemerdash2, Samuel T Savitz3, James E Tisdale4, Eric A Whitsel3,5, Elsayed Z Soliman6, Emily M Thudium7, Carla A Sueta5, Anna M Kucharska-Newton3, Sally C Stearns3, Jo E Rodgers2. 1. College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. 2. UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 3. Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 4. College of Pharmacy, Purdue University, Indianapolis, IN, USA. 5. School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 6. Wake Forest School of Medicine, Winston-Salem, NC, USA. 7. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Abstract
RATIONALE, AIMS, AND OBJECTIVES: Prolongation of the corrected QT (QTc) interval is associated with increased morbidity and mortality. The association between QTc interval-prolonging medications (QTPMs) and risk factors with magnitude of QTc interval lengthening is unknown. We examined the contribution of risk factors alone and in combination with QTPMs to QTc interval lengthening. METHOD: The Atherosclerosis Risk in Communities study assessed 15 792 participants with a resting, standard 12-lead electrocardiogram and ≥1 measure of QTc interval over 4 examinations at 3-year intervals (1987-1998). From 54 638 person-visits, we excluded participants with QRS ≥ 120 milliseconds (n = 2333 person-visits). We corrected the QT interval using the Bazett and Framingham formulas. We examined QTc lengthening using linear regression for 36 602 person-visit observations for 14 160 cohort members controlling for age ≥ 65 years, female sex, left ventricular hypertrophy, QTc > 500 milliseconds at the prior visit, and CredibleMeds categorized QTPMs (Known, Possible, or Conditional risk). We corrected standard errors for repeat observations per person. RESULTS: Eighty percent of person-visits had at least one risk factor for QTc lengthening. Use of QTPMs increased over the 4 visits from 8% to 17%. Among persons not using QTPMs, history of prolonged QTc interval and female sex were associated with the greatest QTc lengthening, 39 and 12 milliseconds, respectively. In the absence of risk factors, Known QTPMs and ≥2 QTPMs were associated with modest but greater QTc lengthening than Possible or Conditional QTPMs. In the presence of risk factors, ≥2 QTPM further increased QTc lengthening. In combination with risk factors, the association of all QTPM categories with QTc lengthening was greater than QTPMs alone. CONCLUSION: Risk factors, particularly female sex and history of prolonged QTc interval, have stronger associations with QTc interval lengthening than any QTPM category alone. All QTPM categories augmented QTc interval lengthening associated with risk factors.
RATIONALE, AIMS, AND OBJECTIVES: Prolongation of the corrected QT (QTc) interval is associated with increased morbidity and mortality. The association between QTc interval-prolonging medications (QTPMs) and risk factors with magnitude of QTc interval lengthening is unknown. We examined the contribution of risk factors alone and in combination with QTPMs to QTc interval lengthening. METHOD: The Atherosclerosis Risk in Communities study assessed 15 792 participants with a resting, standard 12-lead electrocardiogram and ≥1 measure of QTc interval over 4 examinations at 3-year intervals (1987-1998). From 54 638 person-visits, we excluded participants with QRS ≥ 120 milliseconds (n = 2333 person-visits). We corrected the QT interval using the Bazett and Framingham formulas. We examined QTc lengthening using linear regression for 36 602 person-visit observations for 14 160 cohort members controlling for age ≥ 65 years, female sex, left ventricular hypertrophy, QTc > 500 milliseconds at the prior visit, and CredibleMeds categorized QTPMs (Known, Possible, or Conditional risk). We corrected standard errors for repeat observations per person. RESULTS: Eighty percent of person-visits had at least one risk factor for QTc lengthening. Use of QTPMs increased over the 4 visits from 8% to 17%. Among persons not using QTPMs, history of prolonged QTc interval and female sex were associated with the greatest QTc lengthening, 39 and 12 milliseconds, respectively. In the absence of risk factors, Known QTPMs and ≥2 QTPMs were associated with modest but greater QTc lengthening than Possible or Conditional QTPMs. In the presence of risk factors, ≥2 QTPM further increased QTc lengthening. In combination with risk factors, the association of all QTPM categories with QTc lengthening was greater than QTPMs alone. CONCLUSION: Risk factors, particularly female sex and history of prolonged QTc interval, have stronger associations with QTc interval lengthening than any QTPM category alone. All QTPM categories augmented QTc interval lengthening associated with risk factors.
Authors: B M Psaty; T D Koepsell; D Lin; N S Weiss; D S Siscovick; F R Rosendaal; M Pahor; C D Furberg Journal: J Am Geriatr Soc Date: 1999-06 Impact factor: 5.562
Authors: Nancy M Allen LaPointe; Lesley H Curtis; K Arnold Chan; Judith M Kramer; Jennifer Elston Lafata; Jerry H Gurwitz; Marsha A Raebel; Richard Platt Journal: Pharmacoepidemiol Drug Saf Date: 2006-06 Impact factor: 2.890
Authors: Pentti M Rautaharju; Borys Surawicz; Leonard S Gettes; James J Bailey; Rory Childers; Barbara J Deal; Anton Gorgels; E William Hancock; Mark Josephson; Paul Kligfield; Jan A Kors; Peter Macfarlane; Jay W Mason; David M Mirvis; Peter Okin; Olle Pahlm; Gerard van Herpen; Galen S Wagner; Hein Wellens Journal: J Am Coll Cardiol Date: 2009-03-17 Impact factor: 24.094
Authors: Barbara J Drew; Michael J Ackerman; Marjorie Funk; W Brian Gibler; Paul Kligfield; Venu Menon; George J Philippides; Dan M Roden; Wojciech Zareba Journal: Circulation Date: 2010-02-08 Impact factor: 29.690
Authors: Lesley H Curtis; Truls Østbye; Veronica Sendersky; Steve Hutchison; Nancy M Allen LaPointe; Sana M Al-Khatib; Sally Usdin Yasuda; Peter E Dans; Alan Wright; Robert M Califf; Raymond L Woosley; Kevin A Schulman Journal: Am J Med Date: 2003-02-01 Impact factor: 4.965
Authors: Nancy M Allen LaPointe; Anita Chen; Bradley Hammill; Elizabeth DeLong; Judith M Kramer; Robert M Califf Journal: Am Heart J Date: 2003-11 Impact factor: 4.749
Authors: Mala C Mandyam; Elsayed Z Soliman; Alvaro Alonso; Thomas A Dewland; Susan R Heckbert; Eric Vittinghoff; Steven R Cummings; Patrick T Ellinor; Bernard R Chaitman; Karen Stocke; William B Applegate; Dan E Arking; Javed Butler; Laura R Loehr; Jared W Magnani; Rachel A Murphy; Suzanne Satterfield; Anne B Newman; Gregory M Marcus Journal: Heart Rhythm Date: 2013-07-18 Impact factor: 6.343
Authors: Timothy F Simpson; James W Salazar; Eric Vittinghoff; Joanne Probert; Alan Iwahashi; Jeffrey E Olgin; Phillip Ursell; Amy Hart; Ellen Moffatt; Zian H Tseng Journal: JAMA Intern Med Date: 2020-05-01 Impact factor: 21.873
Authors: Magdalene M Assimon; Lily Wang; Patrick H Pun; Wolfgang C Winkelmayer; Jennifer E Flythe Journal: J Am Heart Assoc Date: 2020-06-24 Impact factor: 5.501
Authors: Luigi Isaia Lecca; Igor Portoghese; Nicola Mucci; Maura Galletta; Federico Meloni; Ilaria Pilia; Gabriele Marcias; Daniele Fabbri; Jacopo Fostinelli; Roberto G Lucchini; Pierluigi Cocco; Marcello Campagna Journal: Int J Environ Res Public Health Date: 2020-01-14 Impact factor: 3.390
Authors: Luigi Isaia Lecca; Igor Portoghese; Nicola Mucci; Maura Galletta; Federico Meloni; Ilaria Pilia; Gabriele Marcias; Daniele Fabbri; Jacopo Fostinelli; Roberto G Lucchini; Pierluigi Cocco; Marcello Campagna Journal: Int J Environ Res Public Health Date: 2019-11-28 Impact factor: 3.390